Observational Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 21, 2016; 22(7): 2373-2382
Published online Feb 21, 2016. doi: 10.3748/wjg.v22.i7.2373
CD24 genetic variants contribute to overall survival in patients with gastric cancer
Zhi-Fang Jia, Li-Zhong Wang, Xue-Yuan Cao, Chuan Wang, Dong-Hui Cao, Xing Wu, Li-Li You, Mei-Shan Jin, Yin-Ping Wang, Bao-Sen Zhou, Jing Jiang
Zhi-Fang Jia, Chuan Wang, Dong-Hui Cao, Xing Wu, Li-Li You, Jing Jiang, Division of Clinical Epidemiology, First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Li-Zhong Wang, Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, United States
Xue-Yuan Cao, Department of Gastrointestinal Surgery, First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Mei-Shan Jin, Yin-Ping Wang, Division of Pathology, First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Zhi-Fang Jia, Bao-Sen Zhou, Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110112, Liaoning Province, China
Author contributions: Jia ZF, Wang LZ, Cao XY and Jiang J designed the research; Jia ZF, Wang C, Cao DH, Wu X and You LL performed the research; Wang LZ, Cao XY, Jin MS and Wang YP analyzed the data; Jia ZF and Jiang J wrote the manuscript; Wang LZ, Cao XY and Zhou BS revised the manuscript.
Supported by National Natural Science Foundation of China, No. 81373084 and No. 81273065; the Norman Bethune Program of Jilin University, No. 2013025; and the Youth Fund of the First Hospital of Jilin University, No. JDYY42013014.
Institutional review board statement: The study was reviewed and approved by the ethics committee of the First Hospital of Jilin University.
Informed consent statement: All the participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare no conflicts of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at jiangjing19702000@jlu.edu.cn.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jing Jiang, MD, PhD, Division of Clinical Epidemiology, First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, Jilin Province, China. jiangjing19702000@jlu.edu.cn
Telephone: +86-431-81875408 Fax: +86-431-85654528
Received: May 11, 2015
Peer-review started: May 12, 2015
First decision: July 19, 2015
Revised: August 12, 2015
Accepted: November 30, 2015
Article in press: November 30, 2015
Published online: February 21, 2016
Processing time: 265 Days and 1.8 Hours
Core Tip

Core tip: We evaluated the role of three genetic variants of CD24 in gastric cancer (GC) risk and prognosis using 679 GC cases and 976 controls. We observed that GC cases with the A/A genotype of P-534 (which lies in the CD24 promoter) had a significantly shorter survival (HR = 1.38) especially among patients who lived longer than 2.5 years (HR = 7.55) after adjusting for age, sex, histological type, tumor differentiation, clinical stage and post-operational chemotherapy. Our study provides the first evidence that P-534 site in CD24 may serve as a prognostic marker for gastric cancer.